Gram-negative bacterial lipopolysaccharide - Lipid A domain (LPS)

Gram-negative bacterial lipopolysaccharide (LPS) is a fundamental structural component of the outer membrane of Gram-negative bacteria, providing a robust permeability barrier against toxic compounds [Raetz et al., Annu Rev Biochem, 2002]. It consists of three parts: the O-antigen, a core oligosaccharide, and the highly conserved Lipid A domain, which anchors the molecule into the outer membrane phospholipid bilayer [Wang et al., Microorganisms, 2020]. Lipid A is recognized as the primary endotoxic moiety, as its detection by the human TLR4/MD-2 receptor complex triggers a potent innate immune response [Park et al., Nature, 2009]. In the context of severe infections, excessive LPS release leads to systemic inflammation, sepsis, and potentially fatal septic shock [Stearns-Kurosawa et al., Annu Rev Pathol, 2011]. Therapeutic agents like polymyxins (e.g., Colistin) target the Lipid A domain by binding to its negatively charged phosphate groups, which displaces stabilizing divalent cations and causes lethal membrane disruption [Trimble et al., Cold Spring Harb Perspect Med, 2016]. Despite their efficacy, these drugs face challenges such as significant nephrotoxicity and the emergence of resistance through enzymatic modification of the Lipid A structure [Baron et al., Int J Antimicrob Agents, 2016].

Other names

EndotoxinLipid ALipoglycanGram-negative bacterial outer membrane

Drugs targeting this site, such as polymyxins, act by binding to the negatively charged phosphate groups of the Lipid A domain via electrostatic interactions. This binding displaces essential divalent cations (calcium and magnesium) that stabilize the outer membrane, leading to a loss of membrane integrity, increased permeability, leakage of cytoplasmic contents, and bacterial cell death [Trimble et al., Cold Spring Harb Perspect Med, 2016]. Additionally, some therapeutic strategies involve neutralizing the Lipid A moiety to prevent its interaction with host TLR4 receptors, thereby mitigating the inflammatory cascade associated with sepsis [Opal et al., J Infect Dis, 2014].